A recent research report from Citigroup maintains a "Buy" rating on YIDU TECH and has raised its target price to HK$11, forecasting potential upside of over 96%. As a leading enterprise in China's AI healthcare sector, YIDU TECH is leveraging supportive policies, deep industry expertise, and a comprehensive product portfolio to secure a central role in the wave of medical AI infrastructure development. The report highlights that amid national policies actively promoting "AI + healthcare," YIDU TECH, being a key player, is deeply integrated into national-level AI medical application pilot projects in regions such as Beijing and Henan. The company has developed products like the Doctor Copilot, which significantly enhance operational efficiency in medical institutions and alleviate the workload of healthcare staff. Policy goals include establishing multiple national pilot bases by 2027 and achieving widespread AI technology adoption in secondary and above hospitals by 2030, providing a clear growth roadmap for the company’s business expansion. At the same time, the company’s consumer-facing WeChat mini-program, "Yidu Qianyu," demonstrates solid technical capabilities. In scenario tests conducted by Citigroup, it showed outstanding accuracy and traceability, positioning it in the top tier alongside products such as Ant Group’s Afu and iFlytek’s Xiaoyi. It offers users professional medical consultation support, creating a synergistic business layout that serves both government and hospital clients (To-G) and consumers (To-C). The report specifically acknowledges the company’s substantial accumulation in medical data governance and knowledge construction. Citigroup believes that YIDU TECH’s access to large-scale data sourced from collaborations with top-tier hospitals gives it a unique advantage in data quality and authority. The ability to train models on high-quality real-world data serves as the foundation for medical AI systems to achieve precise diagnosis and decision support. Compared to consumer applications that are still in exploratory phases, the business segments targeting government and hospital clients demonstrate more predictable profitability and directly benefit from increasing hospital AI budgets and national project tenders. Based on its stable To-G business model and clear growth trajectory, Citigroup has raised its financial forecasts for the company. It expects big data platform revenue to grow 17% year-over-year in fiscal 2026 and 30% in fiscal 2027, with the company anticipated to reach breakeven in fiscal 2026. Accordingly, Citigroup has increased YIDU TECH’s target price to HK$11.
Comments